Enanta Pharmaceuticals INC Form 4 insider transactions

Scott T. Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals Inc, reported a transaction in 1,467 shares of common stock on August 8, 2026.

Enanta Pharmaceuticals director Terry Vance was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Lesley Russell received a grant of 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Kristine Peterson was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Yujiro S. Hata received a grant of 20,000 stock options with a $14.17 exercise price, vesting over one year.

Enanta Pharmaceuticals Director Mark G. Foletta was granted 20,000 stock options with an exercise price of $14.17, vesting over one year.

Enanta Pharmaceuticals Director Bruce L.A. Carter was granted 20,000 stock options with an exercise price of $14.17.

Enanta Pharmaceuticals' Chief Legal Officer, Matthew Kowalsky, acquired 5,493 shares through performance-based equity awards, while 1,902 shares were withheld for taxes.

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, acquired 6,562 shares through performance-based awards and disposed of 3,257 shares for tax withholding.

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, acquired 6,875 shares through performance and relative total stockholder return unit vesting, while disposing of 3,413 shares for tax obligations.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, reported the vesting of performance-based stock awards and subsequent share forfeiture for tax obligations.

Enanta Pharmaceuticals' President and CEO, Jay R. Luly, acquired 20,000 shares through performance-based equity awards, partially offset by shares withheld for taxes.

Enanta Pharmaceuticals' Executive Director of Accounting, Kathleen S. Capps, sold 323 shares of common stock at a weighted-average price of $14.23 to cover tax withholding obligations related to restricted stock unit settlements.

Enanta Pharmaceuticals' VP of Finance, Harry R. Trout III, sold 542 shares of common stock at a weighted-average price of $14.23 to cover tax withholding obligations related to restricted stock unit awards.

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, sold 798 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, sold 1,394 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, sold 2,106 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, sold 2,390 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Enanta Pharmaceuticals' President and CEO, Jay R. Luly, sold 4,743 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Kathleen S. Capps, Enanta Pharmaceuticals' Principal Accounting Officer, reported tax-related forfeitures and sales of common stock totaling 292 shares.

Enanta Pharmaceuticals' Vice President of Finance, Harry R. Trout III, reported the sale and forfeiture of common stock to cover tax withholding obligations related to restricted stock unit awards.

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, forfeited 498 shares of common stock to cover tax obligations related to a restricted stock unit settlement.

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, reported a future forfeiture of 753 common shares to cover tax withholdings related to a restricted stock unit settlement.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, forfeited 753 shares of common stock to cover tax obligations related to a restricted stock unit settlement.

Enanta Pharmaceuticals' President and CEO, Jay R. Luly, disposed of 1,885 shares of common stock to cover tax withholding obligations related to a restricted stock unit settlement.

Kathleen S. Capps, an officer at Enanta Pharmaceuticals, Inc., was granted restricted stock units and stock options.

Enanta Pharmaceuticals' VP of Finance, Harry R. Trout III, was granted 6,463 restricted stock units and options to purchase 12,925 shares of common stock.

Enanta Pharmaceuticals' Chief Business Officer, Brendan Luu, was granted 90,000 stock options with an exercise price of $13.66.

Enanta Pharmaceuticals Inc. has granted its Chief Product Strategy Officer, Tara Lynn Kieffer, 100,000 stock options with an exercise price of $13.66.

Enanta Pharmaceuticals has granted its Chief Legal Officer, Matthew Paul Kowalsky, 90,000 stock options with an exercise price of $13.66, vesting over four years.